Effect of Paxlovid treatment during acute COVID-19 on Long COVID onset: An EHR-based target trial emulation from the N3C and RECOVER consortia. [PDF]
PLoS MedicineBackgroundPreventing and treating post-acute sequelae of COVID-19 infection (PASC), commonly known as Long COVID, has become a public health priority. This study tests whether Paxlovid treatment in the acute phase of COVID-19 could help prevent the onset
Alexander Preiss +17 more
doaj +2 more sources
Paxlovid plus glucocorticoids treatment in severe Omicron infected patients with hypoxaemia: A prospective multiple-center cohort study. [PDF]
PLoS ONEBackgroundAdministration of Paxlovid in early stage has been proved to reduce the risk of hospitalization or death by 89% in mild to moderate COVID-19 patients with high-risk. There were few evidences of Paxlovid in severe COVID-19 patients.
Yu-Ji Wang +6 more
doaj +2 more sources
Real-world effectiveness and safety of oral azvudine versus Paxlovid in patients with COVID-19 and pre-existing hypertension: a multicentre, retrospective, cohort study in Henan Province, China [PDF]
BMJ OpenObjectives Azvudine and Paxlovid are the primary antiviral agents for the management of COVID-19. However, there is currently insufficient evidence regarding the effectiveness and safety of these drugs in treating COVID-19 patients with pre-existing ...
Ling Wang +14 more
doaj +2 more sources
Paxlovid utilization and social vulnerability: trends in Connecticut from 2022 to 2023 [PDF]
Antimicrobial Stewardship & Healthcare EpidemiologyThe COVID-19 pandemic disproportionately affected vulnerable communities. Social vulnerability index (SVI) for census tracts with a Paxlovid dispensing site was higher than those without a dispensing site (0.56 vs. 0.45, P < .01).
Laura Hohenstein +2 more
doaj +2 more sources
Detection of Severe Acute Respiratory Syndrome Coronavirus 2 in Pregnant Women Treated with Nirmatrelvir/Ritonavir (Paxlovid) Using Salivary Polymerase Chain Reaction: A Prospective Cohort Study [PDF]
MicroorganismsObjectives: We aim to study the relative viral load using salivary polymerase chain reaction among pregnant women treated with Paxlovid. Methods: Pregnant women with coronavirus disease 2019 were allocated to two groups: those receiving Paxlovid and ...
Chun-Han Tseng +3 more
doaj +2 more sources
A retrospective cohort study of the efficacy and safety of oral azvudine versus nirmatrelvir/ritonavir in elderly hospitalized COVID-19 patients aged over 60 years [PDF]
Acta Pharmaceutica Sinica BAzvudine and nirmatrelvir/ritonavir (Paxlovid) are recommended for COVID-19 treatment in China, but their safety and efficacy in the elderly population are not fully known.
Bo Yu +17 more
doaj +2 more sources
Vaccines, 2023 COVID-19 virus, since the detection of the first case in Wuhan in 2019, has caused a worldwide pandemic with significant human, economic and social costs.
Prabal Chourasia +2 more
exaly +3 more sources
A proof-of-concept study on the genomic evolution of Sars-Cov-2 in molnupiravir-treated, paxlovid-treated and drug-naïve patients [PDF]
, 2022 Little is known about SARS-CoV-2 evolution under Molnupiravir and Paxlovid, the only antivirals approved for COVID-19 treatment. By investigating SARS-CoV-2 variability in 8 Molnupiravir-treated, 7 Paxlovid-treated and 5 drug-naive individuals at 4 time ...
Alteri, Claudia +21 more
core +7 more sources
Effect of nirmatrelvir/ritonavir (Paxlovid) on hospitalization among adults with COVID-19: An electronic health record-based target trial emulation from N3C. [PDF]
PLoS MedicineBackgroundNirmatrelvir with ritonavir (Paxlovid) is indicated for patients with Coronavirus Disease 2019 (COVID-19) who are at risk for progression to severe disease due to the presence of one or more risk factors. Millions of treatment courses have been
Abhishek Bhatia +17 more
doaj +2 more sources
Early Versus Delayed Usage of Paxlovid in Severe Omicron‐Infected Patients With Hypoxemia: A Prospective Multiple‐Center Cohort Study [PDF]
Health Science ReportsBackground and Aims Early stage administration of Paxlovid has been shown to improve the prognosis of mild to moderate COVID‐19 patients with high risk. However, few evidence was validated in severe COVID‐19 patients with hypoxemia.
Yu‐Ji Wang +8 more
doaj +2 more sources